帕罗西汀治疗精神分裂症的辅助作用

目的观察帕罗西汀辅助治疗精神分裂症的疗效。方法入组病例分为伴有抑郁或焦虑症状及不伴有抑郁或焦虑症状两组，原有抗精神病药不变，辅以帕罗西汀治疗，以简明精神病量表（BPRS）、阴性症状量表（SANS）、抑郁自评量表（SDS）、焦虑自评量表（SAS）评定疗效，观察期8周。结果伴有抑郁或焦虑症状组总分较治疗前有显著减少，新出现的副反应轻微。临床疗效总评量表（CGI）显示总有效率为40．2％。结论帕罗西汀可改善精神分裂症伴发的抑郁、焦虑、紧张症状。     

持续的躯体形式疼痛障碍患者抑郁症状的特征及治疗

目的：了解躯体形式疼痛障碍患者伴发的抑郁症状的特征，明确氟西汀对抑郁及焦虑症状的作用特点。方法：选取62例符合ICD－10中持续的躯体形式疼痛障碍诊断标准的患者，于治疗前及治疗第2，4，6周末评定HAMD，HAMA。疗效评定以减分率及有效率为评定指标。结果：氟西汀治疗第六周末，有效率为79．03％，治疗前及治疗第6周末的HAMD各项目分均有显著性差异（P值均＜0．01）；氟西汀治疗六周后，HAMD三个因子减分率分别为：迟滞（75．8％），焦虑／躯体性(焦虑（69．4％），体重（45．2％）；HAMA二个因子减分率分别为：精神性焦虑（70．97％），躯体性焦虑（72．58％）。结论：氟西汀对躯体形式疼痛障碍患者的抑郁及焦虑症状均有缓解作用。氟西汀对躯体疼痛障碍患者的动力缺乏亦有较好疗效。     

肿瘤患者伴发抑郁、焦虑症状的临床治疗

目的：验证帕罗西汀对肿瘤患者伴发的抑郁焦虑症状的治疗作用。方法：采用焦虑自评量表(SAS)、抑郁自评量表(SDS)选取伴焦虑、抑郁症状的肿瘤患者93例，随机分为二组。治疗组：每日口服帕罗西汀10-20mg，共4周，于治疗后进行SAS、SDS测评，并与对照组进行对照。结果：帕罗西汀治疗肿瘤患者伴发的抑郁焦虑症状有效率分别为：77．8％和71．1％，明显高于对照组。结论：帕罗西汀对肿瘤患者的抑郁、焦虑症状均有明显治疗作用。     

帕罗西汀并心理干预治疗卒中后抑郁和焦虑共病者81例临床观察

目的：探讨脑卒中后抑郁和焦虑共病对患者生活能力和神经功能康复的影响，及帕罗西汀合并心理干预临床疗效。方法：将脑卒中伴抑郁和焦虑障碍共病者81名随机分成3组，分别接受单用帕罗西汀治疗（A组）、帕岁西汀并心理治疗（B组）以及单用脑血管药物治疗（C组）。采用斯堪的那维亚脑卒中量表、Barthel指数、汉密尔顿抑郁量表、汉密尔顿焦虑量表评估疗效。结果：脑卒中患者中，抑郁和焦虑的共病率为65．9％，A组、B组各项评分与C组比较，差异均有统计学意义。结论：卒中后抑郁和焦虑病人单用帕罗西汀或合并心理治疗均能促进患者神经功能康复和提高生活质量，且帕罗西汀并心理干预的疗效更好。     

大学生社交焦虑与成人依恋类型关系的研究

目的探讨大学生社交焦虑与成人依恋类型的关系。方法以整群抽样的方式选取大学生324名,用Liebowitz社交焦虑量表（LSAS）、亲密关系体验问卷（ECR-R）、社交苦恼与回避量表（SAD）、自尊量表（SES）、信任量表（TS）和惧怕否定评价量表（FNE）进行测查。结果324名大学生社交焦虑阳性筛查率30.6%。不安全型依恋对社交焦虑阳性的影响作用是对照组的2.45倍。不安全型依恋中恐惧型对社交焦虑的影响作用最大,是对照组的5.59倍;迷恋型次之,为2.10倍。不同依恋类型社交焦虑阳性的被试在社交苦恼、惧怕负性否定评价、自尊和信任他人方面有显著差异。结论大学生成人依恋类型是社交焦虑的重要影响因素。不安全型依恋,尤其是恐惧型对社交焦虑的情绪、认知影响最大。     

疏肝解郁胶囊对老年心血管病患者伴发焦虑情绪的疗效观察

目的：探讨疏肝解郁胶囊对老年心血管病患者伴发焦虑情绪的疗效。方法：将88例伴有焦虑情绪的老年心血管病患者随机分为两组,研究组45例,对照组43例。研究组采用疏肝解郁胶囊治疗,对照组采用帕罗西汀治疗。疗效评定采用汉密尔顿焦虑量表（ HAMA）,主观幸福感评定采用费城老年中心信心量表（ PGC）,副反应评定采用治疗中需处理的不良反应症状量表（ TESS）。结果：①有效率比较：分别为88．4％和94．9％（χ2＝0．43,P＞0．05）;②HAMA比较：两组量表评分较治疗前均降低（P＜0．05）,但治疗2周后研究组较对照组下降更明显（t＝2．4002,P＜0．05）;③PGC量表比较：治疗8周后两组量表总分及各项因子分均较治疗前明显改善（P均＜0．05）,但研究组在总分、激越因子、孤独与不满因子较对照组改善明显（ t＝4．0624,2．7058,2．7306,P均＜0．05）;④不良反应发生率比较：分别为6．98％和43．59％（t＝10．34,P＜0．05）。结论：疏肝解郁胶囊对老年心血管病患者伴发焦虑情绪疗效与帕罗西汀疗效相当,不良反应小,适合临床推广使用。     

帕罗西汀合并加巴喷丁治疗躯体形式障碍对照研究

目的探讨帕罗西汀合并加巴喷丁治疗躯体形式障碍的疗效及安全性。方法 86例躯体形式障碍患者随机分为两组,研究组帕罗西汀合并加巴喷丁进行治疗,对照组单用帕罗西汀,疗程8周。治疗前及治疗后2、4、6、8周末分别应用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、症状自评量表(SCL-90)躯体化因子评定临床疗效,用副反应量表(TESS)评定不良反应。结果治疗后2、4、6、8周末研究组HAMD、HAMA、SCL-90躯体化因子评分与对照组有显著性差异(P0.01)。8周末研究组显效率76.74%,对照组显效率55.81%,研究组显效率高于对照组(χ2=4.214,P0.05)。不良反应均较轻,两组间比较无显著性差异。结论帕罗西汀合并加巴喷丁治疗躯体形式障碍的疗效优于单独应用帕罗西汀,且疗效出现较早,副作用无明显增加。     

认知行为疗法并帕罗西汀治疗惊恐障碍疗效分析

目的评价认知行为疗法并帕罗西汀治疗惊恐障碍的治疗效果。方法将符合中国精神障碍分类与诊断标准的69例惊恐障碍患者随机分为研究组（n=37）和对照组（n=32）。研究组给予认知行为并帕罗西汀治疗,对照组单用帕罗西汀治疗,疗程12周,在入组前和治疗2、4、8、12周末应用临床疗效标准和汉密尔顿焦虑量表（HAMA）评定疗效。完成该研究的60名参与者的数据纳入了结果分析。结果汉密顿焦虑量表总分研究组治疗2周末较治疗前有极显著性下降（t=5.56,P〈0.01）;对照组治疗4周末较治疗前有极显著性下降（t=4.27,P〈0.01）;治疗后2、4、8、12周末研究组疗效显著优于对照组。结论认知行为疗法并帕罗西汀治疗惊恐障碍效果优于单用帕罗西汀治疗。     

帕罗西汀联合丙戊酸镁缓释片治疗抑郁症的临床疗效观察

目的评价帕罗西汀联合丙戊酸镁缓释片治疗抑郁症的疗效及安全性。方法 100例符合CCMD-3抑郁症诊断的病人分为2组,分别给予帕罗西汀联合丙戊酸镁缓释片治疗（治疗组）和单用帕罗西汀治疗（对照组）,疗程均为8周。根据汉密尔顿抑郁量表（HAMD）减分率评定疗效,用副反应量表（TESS）评定用药的安全性,在治疗前和治疗后的1,2,4,6,8周末分别对2组进行评定。结果治疗组和对照组各50例,治疗组总的有效率为77.6%,对照组总有效率为51.2%。2组间,（HAMD）减分率疗效比较差异有统计学意义（t=3.089,P〈0.01）,不良反应的发生率：治疗组不良反应发生率为41%,对照组不良反应的发生率为40%,（TESS）评定两组比较无统计学差异（t=0.088,P〉0.05）;对照组中有8例有过躁狂发作（16.0%）,治疗组中只有1例有过躁狂发作（1.96%）,对照组转躁率高于治疗组,2组比较有统计学差异（t=2.582,P〈0.05）。结论帕罗西汀联合丙戊酸镁缓释片治疗抑郁症疗效可增强,起效快,安全性好。     

帕罗西汀对腹泻型肠易激综合症的疗效观察

目的：观察帕岁西汀对腹泻型肠易激综合征（D—IBS）的疗效。方法：按罗马Ⅱ诊断标准选择45例腹泻型D—IBS患者，给予帕岁西汀10mg／d，疗程12周。治疗前后分别评定D-IBS主要症状、排便频率、粪便性状、汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）。结果：42例患者完成研究，胃肠道主要症状、HAMD、和HAMA评分均明显减低，治疗前后差异有显著性（P〈0．01）。大便次数、性状及腹痛在治疗1周后即明显缓解（P〈0．05），而抑郁、焦虑及精神状态的改善在2周后统计学意义（P〈0．05）。以上观察指标评分呈逐周下降趋势，按意图治疗（ITT）和按方案（PP）分析，治愈率为81．0％，总有效率为100％。结论：帕罗西汀能明显缓解胃肠道症状，改善精神状态，但二者并不完全同步。     

丁螺环酮治疗焦虑症30例临床分析

目的 评价丁螺环酮治疗焦虑症的疗效及副反应。方法 应用丁螺环酮治疗30例焦虑症，应用焦虑自评量表(SAS)及汉密尔顿焦虑量表(HAMA)评定疗效，并作临床疗效评定。结果 治疗后SAS、HAMA分值均明显下降，临床疗效评定显示痊愈率为33．3%，总有效率为90%，除出现口干5例(16．67%)、头昏及眩晕3例(10％)、嗜睡1例(3.33％)外，未见其它不良反应，且症状轻微，勿须作特殊处理。结论 丁螺环酮治疗焦虑症疗效肯定，且副作用轻微。     

生物反馈在焦虑症早期辅助治疗的疗效

目的:观察丁螺环酮、生物反馈在焦虑症早期治疗的临床疗效。方法:36例首发焦虑症患者随机分为3组:帕罗西汀加生物反馈组、帕罗西汀加丁螺环酮组和只用帕罗西汀组。于治疗前及治疗后第1、2周末用汉密尔顿焦虑量表(HAMA)评定疗效。结果:HAMA评分比较,1周末,丁螺环酮组、生物反馈组两组比较无明显差异(P0.05),与帕罗西汀组比较差异显著(q=3.63,4.46;P0.05)。2周末,丁螺环酮组、生物反馈组HAMA两组比较无明显差异(P0.05),丁螺环酮组与帕罗西汀组比较差异显著(q=4.09,P0.05),生物反馈组与帕罗西汀组比较差异显著(q=4.03,P0.01)。3组治疗有效率无显著差异(P0.05)。结论:帕罗西汀联合丁螺环酮、生物反馈在焦虑症早期治疗中对疾病缓解更快。生物反馈有助于改变不良的行为模式。     

曲唑酮治疗焦虑症20例临床分析

目的 验证曲唑酮对焦虑症的疗效。方法 应用曲唑酮治疗20例焦虑症，应用焦虑自评量表(SAS)及Hamilton焦虑量表(HAMA)评定疗效，并作临床疗效评定。结果 治疗后SAS、HAMA分值均明显下降，临床疗效评定显示痊愈率为45％，总有效率为95％，除出现困倦4例、嗜睡2例外，未见不良反应。结论 曲唑酮治疗焦虑症疗效肯定，且副作用轻微。     

大学生社交焦虑易感性的回归分析

目的：探讨大学生社交焦虑易感性与各种可能因素之间的关系。方法：对200名大学本科生施测了社交焦虑量表、羞耻量表、艾森克人格问卷简式量表、应付方式问卷、贝克抑郁量表、特质焦虑问卷。结果：大学生的社交焦虑易感性主要与羞耻感、人格中的精神质、内外向等因素相关；社交焦虑易感性高的个体更易对自己的行为感到羞耻，且缺乏消极的应对方式；而易感性低的个体在人格的精神质、外向方面表现更明显、突出。结论：羞耻感和人格因素中的精神质、内外向是对大学生个体的社交焦虑易感性产生影响的主要因素，对自己行为的羞耻，且不善于使用消极的应对方式，加剧了个体的焦虑体验；个性中的精神质、外倾的特征可以降低大学生的社交焦虑易感性。     

Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration

BACKGROUND: Social anxiety disorder is fairly prevalent among alcohol abusing/dependent subjects. The objective of the present study was to investigate: (a) the incidence of social anxiety symptoms in inpatient alcoholics, (b) the effect of alcohol detoxification on these symptoms, and (c) whether a combined psychotherapeutic/mirtazapine treatment during the post-detoxification phase of alcoholism has a greater impact on the aforementioned symptoms than a non-pharmacological approach. METHOD: Social anxiety symptoms were assessed through the Liebowitz Social Anxiety Scale (LSAS) following a 4-5-week detoxification period in two groups: group A (n=21) that followed a detoxification protocol of cognitive-behavioral orientation and group B (n=33) that was assigned to mirtazapine in addition to the standard protocol. Concomitant psychopathology was monitored through the HARS and HDRS, and level of functioning through the GAS. RESULTS: A marked reduction of social anxiety symptoms was evidenced in both groups. However, patients on mirtazapine improved significantly more compared to controls. LIMITATIONS: A single measure of social anxiety, i.e., the LSAS was used. Also, a longer follow-up period is needed to ascertain remission of social anxiety symptoms. CONCLUSIONS: The present study found a rather high incidence of social anxiety symptoms in inpatient alcoholics which subsided following alcohol detoxification; moreover, it provides preliminary evidence that a combined psychotherapeutic/mirtazapine treatment (30-60 mg/daily) has a greater impact on the aforementioned symptoms than non-pharmacological treatment alone.     

Blushing propensity and psychological distress in people with rosacea

Rosacea is a chronic skin disorder, characterized by persistent painful facial flushing and often accompanied by papules and pustules. To evaluate the psychological and social impacts of rosacea, 31 individuals with rosacea filled in the Blushing Propensity Scale, the Fear of Negative Evaluation Questionnaire, the Depression Anxiety and Stress Scale, the Social Interaction Anxiety Scale and the Social Phobia Scale. The questionnaires were also completed by 86 controls. Participants with extensive facial papules and pustules had higher blushing propensity, stress and social phobia scores than controls or others without papules or pustules. Childhood blushing was also reported more frequently by participants with rosacea than controls. Cognitive-behavioural therapy appeared to be helpful for managing social anxiety in three individuals with rosacea with a fear of blushing. These findings suggest that people with severe rosacea are anxious about the social consequences of blushing and generally prefer to avoid situations that might involve scrutiny by others. Persistent facial flushing could prime interoceptive cues of blushing or increase anxiety about facial coloration in provocative situations. Treatments that target fear of blushing may help to reduce social anxiety in people with severe rosacea. Copyright ? 2011 John Wiley & Sons, Ltd. KEY PRACTITIONER MESSAGE: Blushing propensity scores are elevated in people with severe rosacea. Fear of blushing may contribute to social anxiety and avoidance in such cases. Cognitive-behavioural therapy for fear of blushing may help to reduce social anxiety in people with severe rosacea.     

大学生网络成瘾及其与社交焦虑的关系

目的探讨大学生社交焦虑与网络成瘾倾向的相关。方法使用社交焦虑自评量表和中文网络成瘾量表收集数据。结果①浙江省在校大学生中存在网络成瘾,其中高危险网络成瘾倾向者占3%;②大学生网络成瘾倾向与社交焦虑存在显著正相关;③大学生网络成瘾倾向在性别、年级和文理科上存在不同程度的差异。结论大学生网络成瘾与社交焦虑有紧密关系。     

截肢患者焦虑、抑郁症状的研究

目的 探讨截肢患者伴发焦虑、抑郁症状的特点。方法 对31例截肢患者进行症状自评量表(SCL—90)、焦虑自评量表(SAS)、抑郁自评量表(SDS)、汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)、社会支持评定量表(SSRS)测评。同时以年龄、性别相匹配的31名健康人为对照。结果 截肢患者常有焦虑、抑郁症状,其心身健康程度显著低于对照组,表现在SCL—90中的总分和部分因子分、SDS、SAS、HAMA、HAMD总分显著高于对照组,(P<0.01),而SSRS总分显著低于对照组(P<0.01)。结论 对伴发焦虑、抑郁症状的截肢患者应及时给予心理治疗、抗焦虑剂、抗抑郁剂治疗及良好的家庭照顾和社会支持非常必要。     

The effects of self-administered cognitive therapy on social-evaluative anxiety

Investigated the effecacy of self-administered cognitive therapy (RET) in the treatment of high and chornic social anxiety. Forty-five socially anxious volunteer students, who scored in the upper 15% of 570 students prescreened with the Social Avodance and Distress Scale, were mathced on SAD scores and randomly assigned to self-administered cognitive therapy (RET), a self-administered attention placebo condition. (Logo-therapy), or a no-treatment control condition. Pretest and pssttest measures included the Social Avoidance and Distress Scale (SAD), Fear of Negative Evaulation Scale (ENF), State-Trit Anxiety Inventory, and Rotter's Internal-External Locus of Control Scale. Results indicated that self-administered cognitive therapy significantly decresed social anxiety and fear of negative evaluation and also suggested a generalization of effects as trait anxiety significantly decreased. Comparisons of mean change scores with therapist adminsitered studies lend support to the conclusion that self-administered cognitivae restructuring is an suggest that paritcipants may have attanied therapeutic beneifts as a consistent trend toward decreased anxiety across variables.     

Threat Perception Bias in Nonreferred,Socially Anxious Children

Investigated whether socially anxious children display a threat perception bias. A sample of 252 primary school children ages 8 to 13 years were exposed to ambiguous stories of social situations and instructed to find out as quickly as possible whether a story was scary. Furthermore, children were invited to tell how each story would end and to judge how they would feel when actually confronted with that situation. The main results can be summarized as follows. First, socially anxious children displayed lower thresholds for threat perception than control children. In other words, compared with control children, socially anxious children needed to hear fewer sentences of a story before deciding it was scary. Furthermore, socially anxious children more frequently perceived threat while listening to the stories than did control children. Finally, socially anxious children more often interpreted the stories as threatening and displayed higher levels of negative feelings and cognitions in relation to these stories compared with control children. These findings fit nicely in current information-processing theories of childhood anxiety. An additional aim of this study was to investigate the convergent validity of the social phobia scales of 2 recently developed self-report questionnaires for measuring anxiety disorder symptoms in children: the Spence Children's Anxiety Scale (Spence, 1998) and the Screen for Child Anxiety Related Emotional Disorders (Birmaher et al., 1997). Results indicated that the social phobia scale of the Spence Children's Anxiety Scale and the extended social phobia scale of the Screen for Child Anxiety Related Emotional Disorders correlated substantially with a specific measure of social anxiety, the Social Anxiety Scale for Children-Revised.